Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study to Characterize the Patient Population Diagnosed with Sarcopenia

Next Previous
X
Search
Trial Profile

An Observational Study to Characterize the Patient Population Diagnosed with Sarcopenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions
  • Acronyms SARA-OBS
  • Sponsors Biophytis

    • Most Recent Events

    • 14 Dec 2020 According to a Biophytis media release, data from this study was presented at the 13th international conference on sarcopenia, cachexia andwasting disorders (SCWD) on Saturday December 12th, 2020.
    • 14 Dec 2020 Results published in the Biophytis media release
    • 03 Mar 2020 According to a Biophytis media release, the company will make a presentation at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020,11th March 2020 in Toulouse, France) which will include preliminary results of SARA-OBS study and insights on the SARA-INT recruitment strategies, including inclusion criteria, as well as the baseline characteristics of the first patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top